Potential strategies for improving the outcomes of patients with early stage HER2-positive (HER2+) breast cancer have included dual anti-HER2 therapy. Recent results from the APHINITY trial show a statistically significant, but clinically modest, benefit from the addition of pertuzumab to trastuzumab and chemotherapy. Subsequent trials should focus on biomarkers to identify patients with HER2+ breast cancer who require more-intensive or less-intensive therapy.

中文翻译：

---

乳腺癌：对于HER2阳性乳腺癌，除了APHINITY以外，还有什么？

改善早期HER2阳性（HER2 +）乳腺癌患者预后的潜在策略包括双重抗HER2治疗。APHINITY试验的最新结果显示，在曲妥珠单抗中添加帕妥珠单抗和化疗均具有统计学上的显着意义，但在临床上尚不理想。随后的试验应集中在生物标志物上，以鉴定需要更深入或更不深入治疗的HER2 +乳腺癌患者。